Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of intraperitoneal paclitaxel with S-1 plus cisplatin for gastric cancer with peritoneal metastasis
jRCTs041180079Phase 2Completed
- Sponsor
- Japan Society of Clinical Oncology
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, tegafur and cisplatin in gastric cancer (GC), sponsored by Japan Society of Clinical Oncology. Primary endpoint: 1-year overall survival rate. Started Apr 2017; status: completed.
02
Drugs
paclitaxeltegafurcisplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs041180079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180079.